Jitai Technology has successfully closed a Series D funding round, raising 400 million yuan, and concurrently introduced the Open CGT platform. This platform is designed to address the intricacies of nanodelivery and propel the cell and gene therapy (CGT) industry towards higher levels of quality development. The funding round was jointly led by the Beijing Pharmaceutical and Healthcare Industry Investment Fund and the Daxing District Industrial Investment Fund.

The capital raised will be allocated towards several key initiatives, including automating platform upgrades, advancing proprietary product lines, fostering deeper international strategic collaborations, and attracting top-tier talent. The Open CGT platform emphasizes precise drug delivery, effectively bridging the gap between research, clinical practice, and development.

The platform has already embarked on its inaugural project, which entails developing a liver-targeted CRISPR gene editing therapy utilizing mRNA-LNP technology. Jitai Technology aims to leverage its innovative AI nanodelivery technology to catalyze groundbreaking advancements within the CGT industry.